honeypot link

Merck Manual

Please confirm that you are a health care professional

Prothrombin (Factor II) 20210 Gene Mutation

By

Joel L. Moake

, MD, Baylor College of Medicine

Last full review/revision Jan 2021| Content last modified Jan 2021
Click here for Patient Education
Topic Resources

A genetic mutation causes increased plasma levels of prothrombin (factor II), predisposing to venous thrombosis.

Prothrombin (factor II) is a vitamin K-dependent precursor of thrombin, the terminal enzyme of the coagulation cascade (see figure Pathways in blood coagulation). A single nucleotide mutation in one (or, less commonly, both) of the prothrombin genes at position 20210 results in increased plasma prothrombin levels (with potentially increased thrombin generation) and increases the risk of venous thromboembolism.

The prevalence of the mutation ranges from < 1% to 6.5%, depending on the population studied.

Pathways in blood coagulation

Pathways in blood coagulation

The diagnosis is made by genetic analysis of the prothrombin 20210 gene using blood samples.

Treatment

  • Anticoagulation

Anticoagulation with heparin or low molecular weight heparin, followed by warfarin, is used for venous thrombosis, or for prophylaxis in patients at increased thrombotic risk (eg, by immobilization, severe injury, or surgery).

It is probable, but not yet certain, that the direct oral anticoagulant (DOAC) inhibitors of either thrombin (dabigatran) or factor Xa (eg, rivaroxaban, apixaban) can be used in place of other anticoagulants for this disorder.

Drugs Mentioned In This Article

Drug Name Select Trade
XARELTO
COUMADIN
ELIQUIS
PANHEPRIN
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version

Also of Interest

SOCIAL MEDIA

TOP